Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cibus Inc (CBUS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.14-8.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CBUS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce annual net cash usage to $30M or less | Cibus aims to cut annual cash use to $30 million or less in 2026. | Broken | annual net cash usage exceeds $30 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• Quarterly net cash usage declined approximately 19% for the three month period ended June 30, 2026 as compared to the first quarter of 2026, and approximately 31% from the second quarter of 2025.” “Net cash used in operating activities was $20.9 million for the six months ended June 30, 2026 , compared to $25.4 million in the year-ago period.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making growth business with potential from agricultural traits and sustainable ingredients, rather than an established durable compounder. The long-term thesis is intact, though recent earnings misses and a CEO transition leave execution uncertain.
CBUS carries a durable premium of about 2.7 times versus peers, while the model has low confidence and shows expectations below its benchmark. The evidence labels that premium justified, but the valuation is still expensive and losses make the expectations gap important.
Near-term earnings risk is elevated after consecutive misses, including events in May and August, and management’s guidance could be cut on the next call. Cash use is declining, though the year-end guidance range shifted higher; rice trait launches have also moved later, while biofragrance is generating revenue and pursuing further scale-up.
The multi-year thesis depends on management controlling cash use and turning rice traits and sustainable ingredients into commercial growth. Near term, weaker jobs data or another guidance cut could weigh on the outlook; stronger results and guidance from healthcare sector leaders could support sector momentum.
Over the next one to three years, CBUS has commercial opportunities and some progress on cash discipline, but losses, delayed launches, and a high risk of another earnings miss leave the thesis execution-dependent. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful CEO transition and execution | A supporting condition in Cibus Inc's published investment case. The stated target is Stable management with progress on key objectives. | Under Pressure | CEO transition fails to improve execution or causes disruption | Qualitative: CEO transition executed, but Q2 earnings missed and LATAM rice launch delayed to 2028 Craig Wichner named CEO in June 2026. Q2 2026 earnings missed estimates. LATAM rice launch delayed to 2028. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve strong revenue growth | A primary condition in Cibus Inc's published investment case. The stated target is >=100% YoY revenue growth. | Improving | YoY revenue growth falls below 50% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.82 → $-0.64 · observed estimates
$0.02B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.82 | $15,056,250 | 2 / 3 |
| 2026-07-25 | $-0.82 | $15,056,250 | 2 / 3 |
| 2026-07-26 | $-0.76 | $15,085,667 | 2 / 3 |
| 2026-07-27 | $-0.76 | $15,085,667 | 2 / 3 |
| 2026-07-28 | $-0.76 | $15,085,667 | 2 / 2 |
| 2026-07-29 | $-0.76 | $15,085,667 | 2 / 2 |
| 2026-07-30 | $-0.63 | $13,429,670 | 2 / 3 |
| 2026-07-31 | $-0.76 | $15,085,667 | 2 / 2 |
| 2026-08-01 | $-0.63 | $13,429,670 | 2 / 3 |
| 2026-08-02 | $-0.63 | $13,429,670 | 2 / 3 |
| 2026-08-03 | $-0.63 | $13,429,670 | 2 / 3 |
| 2026-08-04 | $-0.76 | $15,085,667 | 2 / 2 |
| 2026-08-05 | $-0.76 | $15,085,667 | 2 / 2 |
| 2026-08-06 | $-0.76 | $15,085,667 | 2 / 2 |
| 2026-08-07 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-08 | $-0.63 | $13,429,670 | 2 / 3 |
| 2026-08-09 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-10 | $-0.63 | $13,429,670 | 2 / 3 |
| 2026-08-11 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-12 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-13 | $-0.63 | $13,429,670 | 2 / 3 |
| 2026-08-14 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-15 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-16 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-17 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-18 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-19 | $-0.63 | $15,144,500 | 2 / 2 |
| 2026-08-20 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-21 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-22 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-23 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-24 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-25 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-26 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-27 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-28 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-29 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-30 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-08-31 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-01 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-02 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-03 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-04 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-05 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-06 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-07 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-08 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-09 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-10 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-11 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-12 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-13 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-14 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-15 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-16 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-17 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-18 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-19 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-20 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-21 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-22 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-23 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-24 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-25 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-26 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-27 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-28 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-29 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-09-30 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-01 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-02 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-03 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-04 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-05 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-06 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-07 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-08 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-09 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-10 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-11 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-12 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-13 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-14 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-15 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-16 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-17 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-18 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-19 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-20 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-21 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-22 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-23 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-24 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-25 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-26 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-27 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-28 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-29 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-30 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-10-31 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-11-01 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-11-02 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-11-03 | $-0.64 | $12,429,667 | 2 / 2 |
| 2026-11-04 | $-0.64 | $12,429,667 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.